Daniel Eisenberg
Cardiovascular Disease · Burbank, CANPI 1770670515
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 50 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $671 and has fallen 90.6% since, to $63 in 2024. That places this record below the midpoint for cardiovascular disease clinicians in CA, where the typical reported total is $2,142.
Across 50 payments — averaging $24.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$235
- Amgen$180
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$112
- Novartis$67
- Kowa Pharmaceuticals America, Inc.$65
- Pfizer$63
- plus $492 from 16 others
Across 9 payments — averaging $1617.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$15K
- Amgen$5
What the payments were for
- Food & beverage$1,213100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 1 | $235 |
| Amgen | 8 | $180 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $112 |
| Novartis | 3 | $67 |
| Kowa Pharmaceuticals America, Inc. | 2 | $65 |
| Pfizer | 5 | $63 |
| Medtronic(2 entities) | 4 | $62 |
| Johnson & Johnson | 3 | $56 |
| Braemar Manufacturing, LLC | 1 | $56 |
| Abbott | 2 | $45 |
| LSI Solutions Inc | 2 | $39 |
| Actelion Pharmaceuticals US, Inc. | 1 | $36 |
| Edwards Lifesciences | 1 | $29 |
| Akcea Therapeutics, Inc. | 1 | $26 |
| Amarin Pharma, Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Irhythm Technologies, Inc. | 1 | $21 |
| Vertiflex, Inc. | 1 | $19 |
| Boston Scientific | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Getinge USA Sales, LLC | 1 | $12 |
| Biomerieux Inc | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$235
How this compares
$1,213 in reported general payments places this provider in the 40th percentile of 2,184 cardiovascular disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 44 | $52,056 |
| Atorvastatin Calcium | 133 | $1,747 |
| Irbesartan | 41 | $909 |
| Losartan Potassium | 45 | $520 |
| Rosuvastatin Calcium | 17 | $449 |
| Metoprolol Succinate | 23 | $292 |
| Carvedilol | 27 | $286 |
| Amlodipine Besylate | 40 | $207 |
| ClopidogrelClopidogrel Bisulfate | 13 | $163 |
| Furosemide | 17 | $137 |
| Metoprolol Tartrate | 24 | $86 |
| Lisinopril | 24 | $45 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $63 | $52,05644 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Burbank
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
- Wilber SuStanford$1.1M
- Thomas SmithSacramento$942K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.